ре открити при 58/ 1053 (5, 5%) пациенти лекувани с адалимумаб, в сравнение с 2/ 370 (0, 5%) на плацебо.
In the pivotal trials, anti-adalimumab antibodies were identified in 58/ 1053 (5.5%) patients treated with adalimumab, compared to 2/ 370 (0.5%) on placebo.